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Abstract 
The risk of surgical site infection is always present in surgery; the use of prosthetic materials is linked to an increased possibility of infection. 
Breast augmentation and breast reconstruction with implants are gaining popularity in developing countries. Implant infection is the main 
complication related to breast aesthetic and reconstructive surgery. In the present paper, we reviewed the current microbiological knowledge 
about implant infections, with particular attention to risk factors, diagnosis, clinical management, and antibiotic prophylaxis, focusing on 
reports from developing countries. After breast aesthetic surgery, up to 2.9% of patients develop a surgical site infection, with an incidence of 
1.7% for acute infections and 0.8% for late infections. The rate of surgical site infection after post-mastectomy breast reconstruction is 
usually higher, ranging from 1% to 53%. The clinical features are not constant, and bacterial culture with antibiogram is the gold standard for 
diagnosis and for identification of antibiotic resistance. While waiting for culture results, empiric therapy with vancomycin and extended-
spectrum penicillins or cephalosporins is recommended. Some patients require removal of the infected prosthesis. The main methods to bring 
down the risk of infection are strict asepsis protocol, preoperative antibiotic prophylaxis, and irrigation of the surgical pocket and implant 
with an antibiotic solution.  
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Epidemiology 
Implant infection is the main complication related 
to breast aesthetic and reconstructive surgery [1]. After 
breast aesthetic augmentation, up to 2.9% of women 
are affected by infection [2], with an incidence of 
1.7% for acute infections versus an incidence of 0.8% 
for late infections, as confirmed by retrospective 
cohort studies with long-term follow-ups [1]. In 
developing countries, this problem is even more 
prevalent; surgery has a 50% rate of possible 
complications, of which infection is the main 
complication [3]. The rate of surgical site infection 
after post-mastectomy breast reconstruction is usually 
higher, ranging from 1% to 53% [4,5]. In breast 
reconstruction, a higher rate of infection was reported 
with expander implants compared to reconstruction 
with autologous tissue such as latissimus dorsi flaps 
[6]. The highest rates were found in women 
undergoing immediate reconstruction [4]. The reported 
number of infections after mammary augmentation 
and reconstruction is lower than the real incidence, 
because of the lack of a surveillance network of 
patients based on long-time follow-ups. The economic 
commitment for management of implant infections is 
significant. Kirkland et al. [7] reported an increase of 
hospital permanence for surgical site infection of 6.5 
days, with related health care costs. In the United 
States, health care costs for surgical site infection after 
breast surgery were estimated to be about $4,091 [7], 
or $574 in the outpatient setting [9]. In developing 
countries, the risk of complications of surgery – 
including infection – is the second most frequent 
reason for women rejecting immediate breast 
reconstruction after mastectomy [10]. 
 
Risk factors 
Several risk factors associated with an increased 
rate of implant infections have been studied. For 
convenience, it is useful to separate pre-operative, 
intra-operative, and post-operative risk factors. 
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Clinical patient conditions and surgical technique are 
the most important elements in setting the overall risk 
of surgical site infection. Within the preoperative risk 
factors, breast size larger than C cup, body mass index 
greater than 30, smoking, diabetes, prior breast 
surgery, chest wall radiation therapy, and neoadjuvant 
chemotherapy have been reported [6,11,12]. However, 
as found by a recent retrospective study on the 
statistical significance of risk factors, increased body 
mass index, diabetes, tobacco use, and chemotherapy 
do not represent independent risk factors with 
statistical significance [11]. Intraoperatively, the 
surgical technique seems to be able to influence the 
infection rate, as demonstrated by the higher number 
of infective complications associated with periareolar 
or transareolar approaches, probably due to 
contamination of the implant by endogenous flora of 
the nipple or breast ducts. Consequentially, adequate 
skin asepsis can reduce the risk of surgical site 
infections. Axillary node dissection represents a risk 
factor able to increase the chance of implant infection 
by 6.29 times [12]. Reconstructive surgery shows a 
greater risk than does breast augmentation, probably 
due to the higher level of ischemia, scarring, and skin 
atrophy resulting from a longer or repeated surgical 
engagement of the thoraco-mammary area. Surgical 
site infection seems to be more frequent in immediate 
reconstruction rather than in delayed and multi-step 
reconstruction; this finding is probably linked to the 
greater possibility of surgical bed contamination in the 
one-step approach. According to Araco et al. [13], the 
drains placement could be associated with a fivefold 
increased risk of surgical site infections; however, 
McCarthy et al. [14] found no differences in infection 
risk in patients who did and patients who did not have 
drains during surgery.. Francis et al. [11] suggested 
that it could be the lack of drain placement that 
increases the probability of infection, although only 
moderately. Several features of implants, such as 
texture or polyurethane coating [15], do not seem to be 
able to modify the infection rate. Instead, implant 
coating with acellular dermal matrix increases the risk 
of infection, as confirmed by Liu et al. [16] in a case 
report of 470 patients that noted, after immediate 
reconstruction, a 4.2% rate of implant removal due to 
infection for implants coated with acellular dermal 
matrix, compared to 2.4% for non-coated implants. 
With regard to contamination of saline implants, 
although the shell is not permeable to bacteria [17], 
bacteria can enter into the lumen through the implant 
valve [18]. It is yet to be confirmed whether there are 
differences in overall infection rates between silicone 
implants and saline implants. Postoperatively, the 
formation of a seroma or hematoma [17] may 
represent an appropriate pabulum for bacterial 
overgrowth. Other possible predisposing factors 
include adjuvant chemotherapy, breast trauma, nipple 
piercing [19], and all diagnostic and therapeutic 
procedures able to detect bacteremia, even if transient. 
It is worth noting the possibility of hematogenous 
dissemination from a remote focus of infection, with 
secondary colonization of the implant surface [15]. 
Peled et al. found that, after mastectomy and 
immediate reconstruction, adjuvant chemotherapy was 
associated with a higher overall rate of infection (44%) 
compared to neoadjuvant chemotherapy (23%) and 
lack of chemotherapy (25%) [20]. Adhesive bandage 
of the surgical dressing can cause severe contact 
dermatitis with subsequent superinfection of the skin 
and depth diffusion in the implant. However, an 
accurate evaluation of risk factors based on 
prospective studies with long-term follow-ups is not 
yet available. 
As a solution for developing countries with small 
budgets for health care spending, Agrawal suggested 
the reuse of expanders and stressed that, in his 
experience, the complication rate is similar for reused 
or fresh expanders [21]. However, the reuse of 
expanders in developing countries is not 
recommended, as reports have demonstrated an 
increased incidence of complications [22] and post-
implantation development of clinical symptomatology 
with fatigue, fever, shortness of breath, and pleural 
effusion, compatible with infection [23]. According to 
Anger [22], the higher number of complications 
associated with the reused expander could lead to 
greater health care spending than would the purchase 
of a new expander.  
 
Acute infections 
Acute infections represent the most common 
postoperative infections and occur more frequently 
than late infections, usually between the first and the 
sixth week after surgery [15]. The average onset time 
is 10–12 days after surgery. Mainly Gram-positive 
microorganisms of endogenous breast flora are 
involved, such as coagulase-negative staphylococci, 
Staphylococcus aureus, methicillin-resistant S. aureus 
(MSRA), Streptococcus pyogenes, Propionibacterium 
acnes, diphtheroids, lactobacilli, or Bacillus species, 
but rare pathogens may also be involved. The 
endogenous breast flora can reach deeper tissues 
through breast ducts or during surgery. According to 
different studies [11,12], the microorganism most 
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frequently observed is coagulase-negative 
staphylococci but in a recent single retrospective 
review [28], 67% of implant infections were due to S. 
aureus, with methicillin resistance in 68% of these 
cases. In the same study, Gram-negative bacteria were 
reported in only 6% of infections. Typically, the 
clinical features include marked breast erythema, 
edema, warmth with simultaneous onset of rapidly 
evolving pain, deformation, and occasionally 
dehiscence of the surgical wound. Fever and purulent 
drainage are not always present. Leukocytosis is often 
found, but it does not represent a specific marker. The 
patient may have nausea, vomiting, watery diarrhea, 
myalgia, lethargy, and skin rash. In particular, these 
latter symptoms are indicative of toxic shock 
syndrome (TSS), a life-threatening complication 
caused by toxin-producing strains of S. aureus and S. 
pyogenes [29,30]. TSS occurs within 12–24 hours 
after breast implant introduction, much earlier than 
usual surgical site infections [29]. Even reconstruction 
with autologous flaps is not riskless, as demonstrated 
by a case report that described a TSS following a 
DIEP-flap [31]. TSS is characterized by poor local 
signs  along with systemic involvement: fever 
exceeding 38.9°C, hypotension, macular 
erythroderma, nausea, vomiting, diarrhea, myalgia, 
lethargy, respiratory distress syndrome, coagulopathy, 
and rapidly evolving multi-organ failure. For systemic 
involvement, it is lifesaving to recognize TSS 
immediately, remove the prosthesis, and quickly start 
intravenous antibiotic therapy. 
 
Late infections 
The onset time of late infection extends from a few 
months to several years after breast implant 
introduction. The onset time of infections is different 
for saline implants and silicone implants: saline 
implant infections occur within 8 weeks (on average 4 
weeks), while silicone implant infections occur within 
26 weeks (on average 13 weeks) [27]. The earlier 
onset of saline implant infections may be linked to 
contamination during implant filling [28]. After 
augmentation mammaplasty, 0.8% of patients are 
affected by late infections. Late infection usually 
results from bacteremia and secondary colonization of 
prosthesis, also bilaterally [15]. As a result, any 
potential bacterial infection, even in distant places, 
may represent a risk factor and should be recognized 
as early as possible to start a systemic antibiotic 
treatment. Moreover, invasive diagnostic procedures 
and surgery in patients with breast implants should be 
associated with antibiotic prophylaxis. The lack of 
attention to asepsis measures in invasive procedures or 
surgery is another common risk factor for late 
infections. The microorganisms involved can be both 
Gram-positive and Gram-negative, but coagulase-
negative staphylococci and Propionibacterium acnes 
are the most common [32]. The symptoms of late 
infections are less pronounced than those of acute 
infections: delayed wound healing, not marked breast 
pain, mildly erythematous skin, slightly warm and 
stretched skin, drainage not always present and not 
purulent, and prosthesis dislocation. In some cases, 
infection occurs only with general discomfort and 
fatigue. Another major clinical problem is capsular 
contracture caused by chronic inflammation, often 
linked to biofilm formation on the implant surface 
[32]. Biofilm is a sessile community of 
microorganisms, in which cells adhere irreversibly to 
each other on a foreign body surface and produce a 
polymeric matrix, made of polysaccharides and 
glycoproteins. Biofilm is related to antibiotic 
resistance in many subclinical infections. Biofilm 
stimulates inflammation, and as inflammation goes on, 
the risk of capsular contracture increases [33]. The 
main strategy to prevent biofilm formation is the 
application of accurate asepsis protocol. However, 
new techniques have been developed to avoid it: 
steroid therapy and intraluminal antibiotic therapy 
[33]. Jacombs et al. [34] performed a study on a pig 
model, using a circular antibiotic-impregnated mesh 
located under the prosthesis during surgery. Patients 
with medicated implants developed only a mild or 
moderate contracture (Baker I/II) as late as a year 
following the surgery, and the implant surface showed 
a single layer of microorganisms or isolated bacteria 
under an electron microscope. 
 
Rare infections 
Rare infections with acute or delayed onset can be 
caused by atypical mycobacteria commonly present in 
soil, in municipal tap water, and hospital water 
systems [35]. The contamination of water may be 
greater in developing countries due to the lack of 
microbiological checks. A survey of 2,062 
augmentation mammaplasties reported an incidence 
rate of 0.013% for atypical mycobacteria infections 
[36]. However, the real incidence of these infections 
could be much greater because mycobacterial cultures 
are not commonly requested. For atypical 
mycobacteria, the onset time ranges from two weeks 
to over one year [37]. The non-pigmented, rapidly 
growing mycobacterium (RGM) is the most frequently 
isolated microorganism; up to 60%–80% of RGM 
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infections are caused by M. fortuitum group, 
comprising M. chelonae, M. abscessus, and M. 
immunogenum. In developing countries, the reports of 
prosthetic RGM infections are on the rise [37]. 
Clinical features are local erythema and swelling and 
tension as in acute infections caused by Gram-positive 
bacteria, but without systemic involvement. Instead, 
uncommon late infections are due to Streptomyces 
[38], Klebsiella pneumoniae [39], Pasteurella 
multocida [40], Brucella [41], Listeria [42], 
Clostridium perfringens [43], Granulicatella adiacens 
[44], Enterococcus avium [45], Bacteroides fragilis 
[46], and Serratia marcescens [47]. Also, fungal 
infections are unusual; they generally occur late and 
mainly affect immunocompromised patients. Fungal 
infections by Trichosporon, Aspergillus flavus and 
Aspergillus niger, Candida albicans, Curvularia, 
Penicillium, and Paecilomyces variotii have all been 
described [48-50]. According to Saray et al. [51], the 
silicone membrane of saline-filled devices is 
impermeable to Candida and Aspergillus, but both 
fungi are able to spread from outside to inside through 
the injection port. 
 
Diagnosis and management 
The clinical features of breast implant infection are 
not constant. In the literature, both the importance and 
the non-specificity of the clinical framework are 
highlighted [51]. Patients often complain of 
discomfort and tension at the site of implantation, but 
these symptoms are often linked to hydrohematic 
periprosthetic fluid. Fever is generally found, but it is 
not always present [15]. Pain and erythema are present 
in a high percentage of patients. An ultrasound scan is 
able to show periprosthetic fluid in order to identify 
the size and location of the infection and its 
relationship with the implant. However, an ultrasound 
scan does not show whether the periprosthetic fluid is 
infectious or not [52]. The ultrasound has an important 
role in the ultrasound-guided drainage, while other 
imaging techniques have a limited role. All diagnostic 
and therapeutic options aim to eradicate infection and 
rescue the implant. This does not always happen, 
particularly in late infections and rare infections. The 
gold standard for diagnosis and identification of 
antibiotic resistance is bacterial culture with 
antibiogram using aspirated periprosthetic fluids or  
bioptic samples [52]. Blood culture in patients with 
suspected bacteremia is another useful method [52]. 
Cytological and immunohistochemical evaluations are 
necessary in unclear diagnostic cases, which raise the 
problem of differential diagnosis between subclinical 
infection and malignancies such as anaplastic large 
cell lymphoma [52]. The most frequent infections are 
caused by bacteria of endogenous skin flora, 
particularly coagulase-negative staphylococci and S. 
aureus [28]. Before culture and antibiogram, empiric 
therapy with vancomycin is recommended, based on 
the high number of infections due to beta-lactam 
resistant pathogens, among which are methicillin-
resistant S. aureus and coagulase-negative 
staphylococci. While waiting for culture results, 
therapy should include extended-spectrum 
cephalosporins or penicillins to act also on Gram-
negative pathogens [52]. A lack of improvement 
following a prolonged empiric therapy and implant 
removal should raise suspicion of late or rare 
infections. Culture and antibiogram are important in 
identifying the pathogen to set the target therapy 
aimed at eradicating the infection. If fluid aspirate is 
negative in routine culture, a therapy must be carried 
out for two weeks in order to eliminate pathogens not 
identified, and an atypical mycobacterial culture must 
be taken into account. If the patient's condition 
worsens or does not improve within two days, it may 
be necessary to remove the implant and 
microbiologically analyze the material removed. 
Usually, patients with systemic infections and poor 
general conditions require implant removal. The 
removed implant must be analyzed for aerobic 
bacteria, anaerobic bacteria, mycobacteria, and fungi 
[52]. Capsulotomy is not mandatory, but is usually 
done. After prosthesis removal, systemic antibiotics 
should be given for 10–14 days [53], orally in less 
serious cases and intravenously in severe infections. 
Immediate reimplantation is not advised, and the best 
time to perform the reimplantation will depend on the 
pathogen detected and the length of antimicrobial 
therapy necessary to obtain the eradication. 
Reimplantation is often delayed up to three or six 
months, but there are no trials identifying optimal 
timing. In selected cases, after pocket washing with 
saline solution and betadine, the immediate 
reimplantation of new prostheses has been successful 
[54]. The necessity of removing the controlateral 
implant is also a matter of debate. 
 
Antibiotic prophylaxis 
The use of prosthesis for breast aesthetic and 
reconstructive surgery makes antibiotic prophylaxis 
necessary, according to the guidelines for prevention 
of surgical site infection provided by United States 
Centers for Disease Control and Prevention (CDC) 
[24]. Several studies support preoperative antibiotic 
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prophylaxis to reduce the risk of surgical site infection 
(surgical site infection average rates of 14.4% in 
surgery without preoperative antibiotic prophylaxis 
versus 5.8% in surgery with preoperative antibiotic 
prophylaxis) [25]. The guidelines recommend a single 
dose of intravenous first- or second-generation 
cephalosporin before starting anesthetic procedures. 
Surgical time exceeding three hours may require an 
intraoperative dose of antibiotic. In patients with 
allergies to beta-lactam antibiotics, a non-beta-lactam 
antibiotic with adequate spectrum is recommended, 
such as clindamycin or cotrimoxazole. Brand [15], in 
his extensive survey of a group of 73 plastic surgeons, 
showed that preoperative antibiotic prophylaxis, 
irrigation of surgical pocket, and immersion of 
implants in a antiseptic or an antibiotic solution (e.g., 
cephalosporins, bacitracin, neosporin), are usually 
performed in surgical practice. A recent systematic 
review underlines the fact that antibiotic prophylaxis 
in reconstructive surgery lowers the risk of surgical 
site infection; this study also emphasized that 
continuing prophylaxis beyond 24 hours after surgery 
[25] may not be useful, which has already been 
suggested by the CDC. Some studies [26] suggest the 
use of medicated implants to achieve reduction of 
capsular contracture, but further prospective studies 
are needed before recommending a widespread use of 
medicated implants that may increase the selection of 
antibiotic-resistant bacterial strains. 
 
Conclusions 
Infections are significant complications of breast 
implants. The most common pathogens found are 
those residing on breast skin; this consideration is 
useful in directing empirical therapy. The clinical 
presentation does not always provide a clear 
framework, but the presence of fever and leukocytosis 
associated with edema and swelling should always 
suggest the possibility of infection. The frequent 
finding of multi-drug resistance emphasizes the 
importance of culture and antibiogram. More attention 
should be given to the possibility of atypical 
mycobacteria infections, which are on the rise in 
developing countries. Therefore, we recommend  
specific culture to detect the growth of mycobacteria. 
Taking immediate action is essential in order to avoid 
implant removal, especially in patients with late 
infections who requested medical counseling very late. 
Prosthetic infections can be subtle but also very 
aggressive and should be treated with great attention 
until they are fully eradicated. Strict asepsis protocol 
associated with preoperative antibiotic prophylaxis, 
irrigation of the surgical pocket, and implant 
immersion in an antibiotic solution can lower the risk 
of surgical site infection. These tips could be used to 
decrease the risk of infection also increase the number 
of women predisposed to breast plastic surgery and in 
particular to immediate breast reconstruction in 
developing countries. We do not recommend using 
reused expanders to bring down health care costs in 
developing countries due to the higher rate of 
complications with related care costs, as mentioned in 
several reports [22,23].  
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